Propel Bio Management, LLC Akero Therapeutics, Inc. Transaction History
Propel Bio Management, LLC
- $172 Billion
- Q3 2024
A detailed history of Propel Bio Management, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 343,729 shares of AKRO stock, worth $10.5 Million. This represents 5.72% of its overall portfolio holdings.
Number of Shares
343,729
Previous 327,752
4.87%
Holding current value
$10.5 Million
Previous $7.69 Billion
28.25%
% of portfolio
5.72%
Previous 4.99%
Shares
3 transactions
Others Institutions Holding AKRO
# of Institutions
190Shares Held
73.8MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$242 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$217 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$181 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$171 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$160 Million4.29% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.42B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...